These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 2230892)
1. Current urinary mass screening for catecholamine metabolites at 6 months of age may be detecting only a small portion of high-risk neuroblastomas: a chromosome and N-myc amplification study. Kaneko Y; Kanda N; Maseki N; Nakachi K; Takeda T; Okabe I; Sakurai M J Clin Oncol; 1990 Dec; 8(12):2005-13. PubMed ID: 2230892 [TBL] [Abstract][Full Text] [Related]
2. Biology of neuroblastomas in Japan found by screening. Hayashi Y; Hanada R; Yamamoto K Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):342-7. PubMed ID: 1456401 [TBL] [Abstract][Full Text] [Related]
3. Biological aspects of neuroblastomas identified by mass screening in Quebec. Brodeur GM; Look AT; Shimada H; Hamilton VM; Maris JM; Hann HW; Leclerc JM; Bernstein M; Brisson LC; Brossard J; Lemieux B; Tuchman M; Woods WG Med Pediatr Oncol; 2001 Jan; 36(1):157-9. PubMed ID: 11464873 [TBL] [Abstract][Full Text] [Related]
4. Unfavorable DNA ploidy and Ha-ras p21 findings in neuroblastomas detected through mass screening. Kusafuka T; Nagahara N; Oue T; Imura K; Nakamura T; Kobayashi Y; Komoto Y; Fukuzawa M; Okada A; Nakayama M Cancer; 1995 Aug; 76(4):695-9. PubMed ID: 8625168 [TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. Look AT; Hayes FA; Shuster JJ; Douglass EC; Castleberry RP; Bowman LC; Smith EI; Brodeur GM J Clin Oncol; 1991 Apr; 9(4):581-91. PubMed ID: 2066755 [TBL] [Abstract][Full Text] [Related]
6. Disomy 1 with terminal 1p deletion is frequent in mass-screening-negative/late-presenting neuroblastomas in young children, but not in mass-screening-positive neuroblastomas in infants. Kaneko Y; Kobayashi H; Maseki N; Nakagawara A; Sakurai M Int J Cancer; 1999 Jan; 80(1):54-9. PubMed ID: 9935230 [TBL] [Abstract][Full Text] [Related]
7. Neuroblastoma mass screening in late infancy: insights into the biology of neuroblastic tumors. Kerbl R; Urban CE; Ambros IM; Dornbusch HJ; Schwinger W; Lackner H; Ladenstein R; Strenger V; Gadner H; Ambros PF J Clin Oncol; 2003 Nov; 21(22):4228-34. PubMed ID: 14615452 [TBL] [Abstract][Full Text] [Related]
8. There may be two tumor suppressor genes on chromosome arm 1p closely associated with biologically distinct subtypes of neuroblastoma. Takeda O; Homma C; Maseki N; Sakurai M; Kanda N; Schwab M; Nakamura Y; Kaneko Y Genes Chromosomes Cancer; 1994 May; 10(1):30-9. PubMed ID: 7519871 [TBL] [Abstract][Full Text] [Related]
10. Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. Bourhis J; De Vathaire F; Wilson GD; Hartmann O; Terrier-Lacombe MJ; Boccon-Gibod L; McNally NJ; Lemerle J; Riou G; Bénard J Cancer Res; 1991 Jan; 51(1):33-6. PubMed ID: 1988094 [TBL] [Abstract][Full Text] [Related]
11. Chromosomes that show partial loss or gain in near-diploid tumors coincide with chromosomes that show whole loss or gain in near-triploid tumors: evidence suggesting the involvement of the same genes in the tumorigenesis of high- and low-risk neuroblastomas. Tomioka N; Kobayashi H; Kageyama H; Ohira M; Nakamura Y; Sasaki F; Todo S; Nakagawara A; Kaneko Y Genes Chromosomes Cancer; 2003 Feb; 36(2):139-50. PubMed ID: 12508242 [TBL] [Abstract][Full Text] [Related]
12. Different genomic and metabolic patterns between mass screening-positive and mass screening-negative later-presenting neuroblastomas. Nakagawara A; Zaizen Y; Ikeda K; Suita S; Ohgami H; Nagahara N; Sera Y; Akiyama H; Kawakami K; Uchino J Cancer; 1991 Nov; 68(9):2037-44. PubMed ID: 1913552 [TBL] [Abstract][Full Text] [Related]
13. Neuroblastoma. Effect of genetic factors on prognosis and treatment. Brodeur GM; Azar C; Brother M; Hiemstra J; Kaufman B; Marshall H; Moley J; Nakagawara A; Saylors R; Scavarda N Cancer; 1992 Sep; 70(6 Suppl):1685-94. PubMed ID: 1325279 [TBL] [Abstract][Full Text] [Related]
14. Cytogenetic findings and prognosis in neuroblastoma with emphasis on marker chromosome 1. Hayashi Y; Kanda N; Inaba T; Hanada R; Nagahara N; Muchi H; Yamamoto K Cancer; 1989 Jan; 63(1):126-32. PubMed ID: 2910410 [TBL] [Abstract][Full Text] [Related]
15. Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study. Cohn SL; Look AT; Joshi VV; Holbrook T; Salwen H; Chagnovich D; Chesler L; Rowe ST; Valentine MB; Komuro H Cancer Res; 1995 Feb; 55(4):721-6. PubMed ID: 7850780 [TBL] [Abstract][Full Text] [Related]
16. Molecular basis of clinical heterogeneity in neuroblastoma. Brodeur GM; Nakagawara A Am J Pediatr Hematol Oncol; 1992 May; 14(2):111-6. PubMed ID: 1356315 [TBL] [Abstract][Full Text] [Related]
17. Interphase fluorescence in situ hybridization detection of chromosome 17 and 17q region gains in neuroblastoma: are they secondary events? Trakhtenbrot L; Cohen N; Betts DR; Niggli FK; Amariglio N; Brok-Simoni F; Rechavi G; Meitar D Cancer Genet Cytogenet; 2002 Sep; 137(2):95-101. PubMed ID: 12393279 [TBL] [Abstract][Full Text] [Related]
18. Different karyotypic patterns in early and advanced stage neuroblastomas. Kaneko Y; Kanda N; Maseki N; Sakurai M; Tsuchida Y; Takeda T; Okabe I; Sakurai M Cancer Res; 1987 Jan; 47(1):311-8. PubMed ID: 3791218 [TBL] [Abstract][Full Text] [Related]
19. Problems of mass screening for neuroblastoma: analysis of false-negative cases. Ishimoto K; Kiyokawa N; Fujita H; Yabuta K; Ohya T; Miyano T; Shinohara T; Sera Y J Pediatr Surg; 1990 Apr; 25(4):398-401. PubMed ID: 2329455 [TBL] [Abstract][Full Text] [Related]
20. A neuroblastoma cell line derived from a case detected through a mass screening system in Japan: a case report including the biologic and phenotypic characteristics of the cell line. Hiraiwa H; Hamazaki M; Takata A; Kikuchi H; Hata J Cancer; 1997 May; 79(10):2036-44. PubMed ID: 9149033 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]